Cal­lid­i­tas bets up to $102M on a biotech buy­out, snag­ging a once-failed PBC drug

Af­ter spend­ing years de­vel­op­ing its oral for­mu­la­tion of the cor­ti­cos­teroid budes­onide, Swe­den’s Cal­lid­i­tas now has its sights set on the pri­ma­ry bil­iary cholan­gi­tis field. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.